IGF-I in mammary tumorigenesis and diabetes

Anticancer Research

Volumn 24, Issue 5 A, 2004, Pages 2953-2965

  Cocca, Claudia ^a   Nuñez, Mariel ^a   Gutiérrez, Alicia ^a   MartíN, Gabriela ^a   Cricco, Graciela ^a   Medina, Vanina ^a   Mohamad, Nora ^a   Rivera, Elena ^a   Bergoc, Rosa ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Diabetes; Insulin growth factor I; Insulin growth factor I receptor; Mammary carcinogenesis; Rats

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIESTROGEN; DROLOXIFENE; FULVESTRANT; N BUTYL 11 (3,17BETA DIHYDROXYESTRA 1,3,5(10) TRIEN 7ALPHA YL) N METHYLUNDECANAMIDE; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; TAMOXIFEN;

BREAST CANCER; BREAST CARCINOGENESIS; CANCER THERAPY; CELL DEATH; CELL DIFFERENTIATION; CELL GROWTH; CELL MATURATION; CELL PROLIFERATION; CELL SURVIVAL; CELL TRANSFORMATION; DIABETES MELLITUS; DRUG EFFECT; DRUG MECHANISM; DRUG RESPONSE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INSULIN RESISTANCE; MODULATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; BREAST NEOPLASMS; CELL TRANSFORMATION, NEOPLASTIC; DIABETES MELLITUS; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MAMMARY NEOPLASMS, EXPERIMENTAL;

EID: 6444230374     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (153)

1. Parkin DM, Pisani P and Ferlay J: Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 80: 827841, 1999.
2. Sankaranarayanan R, Swaminathan R and Black RJ: Global variations in cancer survival. Study Group on Cancer Survival in Developing Countries. Cancer 78: 2461-2464, 1996.
3. Laura EA, de Larminat S and Azcon P: Tumor regional registry of the southern Buenos Aires province. Data of the first biennial, 1989-1990. Medicina 55: 223-231, 1993.
4. LeRoith D, Bondy C, Yakar S, Liu JL and Butler A: The somatomedin hypothesis. Endocr Rev 22: 53-74, 2001.
5. Macaulay VM: Insulin-like growth factors and cancer. Br J Cancer 65: 311-320, 1992.
6. Barreca A and Minuto F: Somatomedins: Chemical and functional characteristics of the different molecular forms. J Endocrinol Invest 12: 279-293, 1989.
7. LeRoith D and Roberts CT Jr: The insulin-like growth factor system and cancer. Cancer Lett 195: 127-37, 2003.
8. Bondy CA, Werner AH, Roberts CT Jr and LeRoith D: Cellular pattern of insulin-like growth factor-I (IGF-I) and type I IGF receptor gene expression in early organogenesis: comparison with IGF-II gene expression. Mol Endocrinol 4: 1386-1398, 1990.
9. Rudman D, Feller AG, Nagraj HS, Gergans GA, Lalitha PY, Goldberg AF; Schlenker RA, Cohn L, Rudman IW and Mattson DE: Effects of human growth hormone in men over 60 years old. New Engl J Med 525: 1-6, 1990.
10. Velasco B, Cacicedo L, Escalada J, Lopez-Fernandez J, and Sanchez-Franco F: Growth hormone gene expression and secretion in aging rats is age dependent and not age-associated weight increase related. Endocrinol 139: 1314-1320, 1998.
11. Rickard SE, Yuan YV and Thompson LU: Plasma insulin-like growth factor I levels in rats are reduced by dietary supplementation of flaxseed or its lignan secoisolariciresinol diglycoside. Cancer Lett 161: 47-55, 2000.
12. Borofsky ND, Vogelman JH, Krajcik RA and Orentreich N: Utility of insulin-like growth factor-1 as a biomarker in epidemiologic studies. Clin Chem 48: 2248-2251, 2002.
13. Ullrich A, Gray A, Tam AW, Yang-Feng T, Tsubokawa M, Collins C, Henzel W, Le Bon T, Kathuria S, Chen E, Jacobs S, Francke U, Ramachandran J and Fujita-Yamaguchi Y: Insulin-like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity. EMBO J 5: 2503-2512, 1986.
14. Steele-Perkins G, Turner J, Edman JC, Hari J, Pierce SB, Stover C, Rutter WJ and Roth RA: Expression and characterization of a functional human insulin-like growth factor I receptor. J Biol Chem 263: 11486-11492, 1988.
15. Frattali AL, Treadway JL and Pessin JE: Transmembrane signaling by the human insulin receptor kinase. Relationship between intramolecular beta subunit trans- and cis- autophosphorylation and substrate kinase activation. J Biol Chem 267: 19521-19528, 1992.
16. Frattali AL and Pessin JE: Relationship between alpha subunit ligand occupancy and beta subunit autophosphorylation in insulin/insulin-like growth factor-1 hybrid receptors. J Biol Chem 268: 7393-7400, 1993.
17. Kato MV, Faria TN, Stannard B, Roberts CT Jr and LeRoith D: Role of tyrosine kinase activity in signal transduction by the insulin-like growth factor-I (IGF-I) receptor. Characterization of kinase-deficient IGF-I receptors and the action of an IGF-I-mimetic antibody (alpha IR-3). J Biol Chem 268: 2655-2661, 1993.
18. LeRoith D, Werner H, Beitner-Johnson D and Roberts CT Jr: Molecular and cellular aspects of the insulin-like growth factor I receptor. Endoc Rev 16: 143-163, 1995.
19. Moxham CP, Duronio V and Jacobs S: Insulin-like growth factor I receptor beta-subunit heterogeneity. Evidence for hybrid tetramers composed of insulin-like growth factor I and insulin receptor heterodimers. J Biol Chem 264: 13238-13244, 1989.
20. Jones JI and Clemmons DR: Insulin-like growth factors and their binding proteins: biological actions. Endocrine Rev 16: 3-34, 1995.
21. Benito M, Valverde AM and Lorenzo M: IGF-I: a mitogen also involved in differentiation processes in mammalian cells. Int J Biochem Cell Biol 28: 499-510, 1996.
22. Louvi A, Accili D and Efstratiaidis A: Growth-promoting interaction of IGF-II with the insulin receptor during mouse embryonic development. Dev Bio 189: 33-48, 1997.
23. Baserga R: The contradictions of the insulin-like growth factor 1 receptor. Oncogene 19: 5574-5581, 2000.
24. Kiess W, Haskell JF, Lee L, Greenstein LA, Miller BE, Aarson AL, Rechler MM and Nissley SP: An antibody that blocks insulin-like growth factor (IGF) binding to the type II IGF receptor is neither an agonist nor an inhibitor of IGF-stimulated biologic responses in L6 myoblasts. J Biol Chem 262: 12745-12751, 1987.
25. Minniti CP, Kohn EC, Grubb JH, Sly WS, Oh Y, Muller HL, Rosenfeld RG and Helman LJ: The insulin-like growth factor II (IGF-II)/mannose 6-phosphate receptor mediates IGF-II-induced motility in human rhabdomyosarcoma cells. J Biol Chem 267: 9000-9004, 1992.
26. Kiess W, Yang Y, Kessler U and Hoeflich A: Insulin-like growth factor II (IGF-II) and the IGF-II/mannose-6-phosphate receptor: the myth continues. Horm Res 41: 66-73, 1994.
27. Favoni R and De Cupis A: The role of polypeptide growth factors in human carcinomas: new targets for a novel pharmacological approach. Pharmacol Rev 52: 179-206, 2000.
28. Kelley KM, Oh Y, Gargosky SE, Gucev Z, Matsumoto T, Hwa V, Ng L, Simpson D and Rosenfeld RG: Insulin-like growth factor-binding proteins (IGFBPs) and their regulatory dynamics. Int J Biochem Biol 28: 619-637, 1995.
29. Yamanaka Y, Wilson EM, Rosenfeld RG and Oh Y: Inhibition of insulin receptor activation by insulin-like growth factor binding proteins. J Biol Chem 272: 30729-30734, 1997.
30. Oh Y: IGF-independent regulation of breast cancer growth by IGF binding proteins. Breast Cancer Res Treat 47: 283-93, 1998.
31. Hwa V, OH Y and Rosenfeld R: The insulin-like growth factor-binding protein (IGFBP) superfamily. Endocr Rev 20: 761-787, 1999.
32. Oh Y, Nagalla SN, Yamanaca Y, Kim H, Wilson L and Rosenfeld RG: Synthesis and characterization of insulin-like growth factor-binding protein (IGFBP)-7. Recombinant human mac25 protein specifically binds IGF-I and -II. J Biol Chem 277: 30322-30325, 1996.
33. Kato MV: A secreted tumor-suppressor, mac25, with activin-binding activity. Mol Med 6: 126-35, 2000.
34. Myers MG Jr, Grammer TC, Wang LM, Sun XJ, Pierce JH, Blenis J and White MF: Insulin receptor substrate-1 mediates phosphatidylinositol 3′-kinase and p70S6k signaling during insulin, insulin-like growth factor-1, and interleukin-4 stimulation. J Biol Chem 269: 28783-28789, 1994.
35. 7eitner-Johnson D, Blakesley VA, Shen-Orr Z, Jimenez M, Stanndard B, Wang LM, Pierce J and LeRoith D: The proto-oncogene product c-Crk associates with insulin receptor substrate-1 and 4PS. Modulation by insulin growth factor-I (IGF) and enhanced IGF-I signaling. J Biol Chem 271: 9287-9290, 1996.
36. Pelicci G, Lanfrancone L, Salcini AE, Romano A, Mele S, Borrello MG, Gegatto O, Di Fiore PP and Pelicci PG: Constitutive phosphorylation of She proteins in human tumors. Oncogene 11: 899-907, 1995.
37. Doerr M and Jones J: The roles of integrins and extracellular matrix proteins in the insulin-like growth factor I-stimulated chemotaxis of human breast cancer cells. J Biol Chem 277: 2443-2447, 1996.
38. Guvakova M and Surmacz E: Overexpressed IGF-I receptors reduce estrogen growth requirements, enhance survival, and promote E-cadherin-mediated cell-cell adhesion in human breast cancer cells. Exp Cel Res 231: 149-162, 1997.
39. Adesanya OO, Zhou J, Samathanam C, Powell-Braxton L and Bondy CA: Insulin-like growth factor 1 is required for G2 progression in the estradiol-induced mitotic cycle. Proc Natl Acad Sci USA 96: 3287-3291, 1999.
40. LeRoith D and Zick Y: Recent advances in our understanding of insulin action and insulin resistance. Diabetes Care 24: 588-597, 2001.
41. Enoch T and Nurse P: Coupling M phase and S phase: controls maintaining the dependence of mitosis on chromosome replication. Cell 65: 921-923, 1991.
42. Furlanetto RW, Harwell SE and Frick KK: Insulin-like growth factor-I induces cyclin-D1 expression in MG63 human osteosarcoma cells in vitro. Mol Endocrinol 8: 510-517, 1994.
43. Sara VR and Hall K: Insulin-like growth factors and their binding proteins. Physiol Rev 70: 591-614, 1990.
44. Giudice LC: Insulin-like growth factors and ovarian follicular development. Endocr Rev 13: 641-669, 1992.
45. Cohick WS and Clemmons DR: The insulin-like growth factors. Annu Rev Physiol 55: 131-153, 1993.
46. Stiles CD, Capone GT, Scher CD, Antoniades HN, Van Wyk JJ and Pledger WJ: Dual control of cell growth by somatomedins and platelet-derived growth factor. Proc Natl Acad Sci USA 76: 1279-1283, 1979.
47. Rubin R and Baserga R: Insulin-like growth factor-I receptor. Its role in cell proliferation, apoptosis, and tumorigenicity. Lab Invest 73: 311-331, 1995.
48. Baserga R: The IGF-IR in normal and abnormal growth. In: Hormones and Growth Factors in Development and Neoplasia (Dickson R and Salomon DS, eds). NY, USA, Wiley-Liss Inc. 1998, pp 269-287.
49. Baserga R: The double life of the IGF-I receptor. Receptor 2: 261-266, 1992.
50. Sell C, Dumenil G, Deveaud C, Miura M, Coppola D, De Angelis T, Rubin R, Efstratiadis A and Baserga R: Effect of a null mutation of the insulin-like growth factor I receptor gene on growth and transformation of mouse embryo fibroblasts. Mol Cell Biol 14: 3604-3612, 1994.
51. Baserga R: The insulin-like growth factor I receptor: a key to tumor growth? Cancer Res 55: 249-252, 1995.
52. Baserga R, Kongo A, Rubini M, Frisco M and Valentinis B: The IGF-I receptor in cell growth, transformation and apoptosis. Biochem Biophys Acta 1332: F105-F126, 1997.
53. Heron-Milhavet L, Karas M, Goldsmith CM, Baum BJ and LeRoith D: Insulin-like growth factor-I (IGF-I) receptor activation rescues UV-damaged cells through a p38 signaling pathway. Potential role of the IGF-I receptor in DNA repair. J Biol Chem 276: 18185-18192, 2001.
54. Resnicoff M, Sell C, Rubini M, Coppola D, Ambrose D, Baserga R and Rubin R: Rat glioblastoma cells expressing an antisense RNA to the insulin-like growth factor-1 (IGF-1) receptor are nontumorigenic and induce regression of wild-type tumors. Cancer Res 54: 2218-2222, 1994a.
55. Resnicoff M, Coppola D, Sell C, Rubin R, Ferrone S and Baserga R: Growth inhibition of human melanoma cells in nude mice by antisense strategies to the type 1 insulin-like growth factor receptor. Cancer Res 54: 4848-4850, 1994b.
56. Shapiro DN, Jones BG, Shapiro LH, Dias P and Houghton PJ: Antisense-mediated reduction in insulin-like growth factor-I receptor expression suppresses the malignant phenotype of a human alveolar rhabdomyosarcoma. J Clin Invest 94: 1235-1242, 1994.
57. Resnicoff M, Burgaud JL, Rotman HL, Abraham D and Baserga R: Correlation between apoptosis, tumorigenesis, and levels of insulin-like growth factor I receptors. Cancer Res 55: 3739-3741, 1995.
58. Lee CT, Wu S, Gabrivolich D, Chen H, Nadaf-Ranrov S, Ciernick IF and Carbone DP: Antitumor effects of an adenovirus expressing antisense insulin-like growth factor I receptor on human lung cancer cell lines. Cancer Res 56: 3038-3041, 1996.
59. Liu X, Turbyville T, Fritz A and Whitesell L: Inhibition of insulin-like growth factor I receptor expression in neuroblastoma cells induces the regression of established tumors in mice. Cancer Res 58: 5432-5438, 1998.
60. Prager D, Li HL, Asa S and Melmed S: Dominant negative inhibition of tumorigenesis in vivo by human insulin-like growth factor I receptor mutant. Proc Natl Acad Sci USA 91: 2181-2185, 1994.
61. D'Ambrosio C, Ferber A, Resnikoff M and Baserga R: A soluble insulin-like growth factor I receptor that induces apoptosis of tumor cells in vivo and inhibits tumorigenesis. Cancer Res 56: 4013-4020, 1996.
62. Rininsland F, Johnson TR, Chernicky CL, Schulze E, Burfeind B and Ilan J: Suppression of insulin-like growth factor type I receptor by a triple-helix strategy inhibits IGF-I transcription and tumorigenic potential of rat C6 glioblastoma cells. Proc Natl Acad Sci USA 94: 5854-5859, 1997.
63. Reiss K, D'Ambrosio C, Tu X, Tu C and Baserga R: Inhibition of tumor growth by a dominant negative mutant of the insulin-like growth factor I receptor with a bystander effect. Clin Cancer Res 4: 2647-2655, 1998.
64. Fisher DE: Apoptosis in cancer therapy: crossing the threshold. Cell 78: 539-542, 1994.
65. Valentinis B and Baserga R: IGF-I receptor signalling in transformation and differentiation. Mol Path 54:133-137, 2001.
66. Scher CD, Shepard RC, Antoniades HN and Stiles CD: Platelet-derived growth factor and the regulation of the mammalian fibroblast cell cycle. Biochim Biophys Acta 560: 217-241, 1979.
67. Petley T, Graff K, Jiang W and Florini J: Variation among cell types in the signaling pathways by which IGF-I stimulates specific cellular responses. Horm Metab Res 31: 70-76, 1999.
68. Navarro M, Barenton B, Garandel V, Schnekenburger J and Bernardi H: Insulin-like growth factor I (IGF-I) receptor overexpression abolishes the IGF requirement for differentiation and induces a ligand-dependent transformed phenotype in C2 inducible myoblasts. Endocrinol 138: 5210-5219, 1997.
69. Valtieri M, Tweardy DJ, Caracciolo D, Johnson K, Mavilio F, Altmann S, Santoli D and Rovera G: Cytokine-dependent granulocytic differentiation. Regulation of proliferative and differentiative responses in a murine progenitor cell line. J Immunol 138: 3829-3835, 1987.
70. Ward AC, Smith L, de Koning JP, van Aesch Y and Touw IP: Multiple signals mediate proliferation, differentiation, and survival from the granulocyte colony-stimulating factor receptor in myeloid 32D cells. J Biol Chem 274: 14956-14962, 1999.
71. Brown G, Choudhry MA, Durham J, Drayson MT and Michael RH: Monocytically differentiating HL60 cells proliferate rapidly before they mature. Exp Cell Res 253: 511-518, 1999.
72. Liu Q, Ning W, Dantzer R, Freund GG and Kelley KW: Activation of protein kinase C-zeta and phosphatidylinositol 3′-kinase and promotion of macrophage differentiation by insulin-like growth factor-I. J Immunol 160: 1393-1401, 1998.
73. Reece RP, Turner CW and Hill RT: Mammary gland development in the hypophysectomized albino rats. Proc Soc Exp Biol Med 34: 204-217, 1936.
74. Gardner WU: Growth of the mammary gland in mice. Proc Soc Exp Biol Med 45: 835-837, 1942.
75. Lyons WR, Li CH and Johnson RE: The hormonal control of mammary growth and lactation. Rec Prog Horm Res 14: 219-248, 1958.
76. Kleinberg DL: Role of IGF-I in normal mammary development. Breast Cancer Res Treat 47: 201-208, 1998.
77. Ruan W, Newman CB and Kleinberg DL: Intact and aminoterminally shortened forms of insulin-like growth factor I induce mammary gland differentiation and development. Proc Natl Acad Sci USA 89: 10872-10876, 1992.
78. Ruan W, Catenese V, Wieczorek R, Feldman M and Kleimberg DL: Estradiol enhances the stimulatory effect of insulin-like growth factor-I (IGF-I) on mammary development and growth hormone-induced IGF-I messenger ribonucleic acid. Endocrinology 136: 1296-1302, 1995.
79. Ruan W and Kleinberg DL: Insulin-like growth factor I is essential for terminal end bud formation and ductal morphogenesis during mammary development. Endocrinology 140: 5075-5081, 1999.
80. Kleinberg DL, Feldman M and Ruan W: IGF-I: an essential factor in terminal end bud formation and ductal morphogenesis. J Mammary Gland Biol Neopl 5: 7-17, 2000.
81. Staszewski J: Age at menarche and breast cancer. J Natl Cancer Inst 47: 935-940, 1971.
82. Trichopoulos D, MacMahon B and Cole P: Menopause and breast cancer risk. J Natl Cancer Inst 48: 605-613, 1972.
83. Lambe M, Hsieh CC, Chan HW, Ekbom A, Trichopoulus D and Adami HO: Parity, age at first and last birth, and risk of breast cancer: a population-based study in Sweden. Breast Cancer Res Treat 38: 305-311, 1996.
84. Hansen RK and Bissel MJ: Tissue architecture and breast cancer: the role of extracellular matrix and steroid hormones. Endocrine-Related Cancer 7: 95-113, 2000.
85. Ahmed ST, Manni A and Gray G: Characterization and hormonal regulation of radioimmunoassayable IGF-I (insulin-like growth factor I) like activity and IGF-binding proteins secreted by human breast cancer cells. Anticancer Res 10: 1217-23, 1990.
86. Yee D, Paik S, Lebovic GS, Marcus RR, Favoni RE, Cullen KJ, Lippman ME and Rosen N: Analysis of insulin-like growth factor I gene expression in malignancy: evidence for a paracrine role in human breast cancer. Mol Endocrinol 3: 509-517, 1989.
87. Rasmussen AA and Cullen KJ: Paracrine/autocrine regulation of breast cancer by the insulin-like growth factors. Breast Cancer Res Treat 47: 219-233, 1998.
88. Cocca C, Binda M, Martín G, Rivera E, Davio C, Cricco G, Lemos B, Fitzsimons C, Levin E, Croci M and Bergoc R: Experimental diabetes and cancer. Medicina 55: 492, 1995.
89. Cocca C, Martín G, Rivera ES, Davio C, Cricco G, Lemos B, Fitzsimons C, Gutiérrez A, Levin E, Levin R, Croci M and Bergoc R: An experimental model of diabetes and cancer in rats. Eur J Cancer 34: 889-894, 1998.
90. Cocca C, Gutiérrez A, Croci M, Martín G, Nunez M, Cricco G, Rivera E and Bergoc RM: Suppression of mammary gland tumorigenesis in diabetic rats. Cancer Detect Prevent 27: 37-46, 2003.
91. Yee D, Cullen KJ, Paik S, Perdue JF, Lippman ME and Rosen N: Insulin-like growth factor II mRNA expression in human breast cancer. Cancer Res 48: 6691-6696, 1988.
92. Cullen KJ, Allison A, Martire I, Ellis M and Singer C: Insulin-like growth factor expression in breast cancer epithelium and stroma. Breast Cancer Res Treat 22: 21-29, 1992.
93. Pollak MN: Endocrine effects of IGF-I on normal and transformed breast epithelial cells: potential relevance to strategies for breast cancer treatment and prevention. Breast Cancer Res Treat 47: 209-217, 1998.
94. Hankinson SE, Willet WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, Rosner B, Speizer FE and Pollak M: Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 351: 1393-1396, 1998.
95. Sachdev D and Yee D: The IGF system and breast cancer. Endocr Relat Cancer 8: 197-209, 2001.
96. Pekonen F, Partanen S, Makinen T and Rutanen EM: Receptors for epidermal growth factor and insulin-like growth factor I and their relation to steroid receptors in human breast cancer. Cancer Res 48: 1343-1347, 1988.
97. Pollak MN, Perdue JF, Margolese RG, Baer K and Richard M: Presence of somatomedin receptors on primary human breast and colon carcinomas. Cancer Letters 38: 223-230, 1987.
98. Surmacz E: Function of the IGF-I receptor in breast cancer. J Mammary Gland Biol Neoplasia 5: 95-105, 2000.
99. Dickson RB and Lippman ME: Growth factors in breast cancer. Endocr Rev 16: 559-589, 1995.
100. Lee AV and Yee D: Insulin-like growth factors and breast cancer. Biomed Pharmacother 49: 415-421, 1995.
101. Peyrat JP and Bonneterre J: Type 1 IGF receptor in human breast diseases. Breast Cancer Res Treat 22: 59-67, 1992.
102. Papa V, Gliozzo B, Clark GM, McGuire WL, Moore D, Fujita-Yamaguchi Y, Vigneri R, Golfine ID and Pezzino V: Insulin-like growth factor-I receptors are overexpressed and predict a low risk in human breast cancer. Cancer Res 53: 3736-3740, 1993.
103. Pezzino V, Papa V, Milazzo G, Giozzo B, Russo P and Scalia PL: Insulin-like growth factor-I (IGF-I) receptors in breast cancer. Ann N Y Acad Sci 784: 189-201, 1996.
104. Resnik JL, Reichart DB, Huey K, Webster NJ and Seely BL: Elevated insulin-like growth factor I receptor autophosphorylation and kinase activity in human breast cancer. Cancer Res 58: 1159-1164, 1998.
105. Peyrat JP and Bonneterre J: Type 1 IGF receptor in human breast diseases. Breast Cancer Res Treat 22: 59-67, 1992.
106. Cocca C, Gutiérrez A, Croci M, Martín G, Nunez M, Cricco G, Medina V, Mohamad N, Rivera E and Bergoc RM: Changes on the IGF-IR expression associated with malignant mammary transformation. Medicina 63: 641, 2003.
107. Baker J, Liu J-P, Robertson EJ and Efstratiadis A: Role of insulin-like growth factors in embryonic and postnatal growth. Cell 75: 73-92, 1993.
108. Liu J-P, Baker J, Perkins AS, Robertson EJ and Efstratiadis A: Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf-1r). Cell 75: 59-72, 1993.
109. Werner H, Shalita-Chesner M, Abramovitch S, Idelman G, Shaharabani-Gargir L and Glaser T: Regulation of the insulin-like growth factor-I receptor gene by oncogenes and antioncogenes: implications in human cancer. Mol Genet Metab 71: 315-320, 2000.
110. Abramovitch S, Glaser T, Ouchi T and Werner H: BRCA1-Sp1 interactions in transcriptional regulation of the IGF-IR gene. FEBS Lett 24: 149-154, 2003.
111. Werner H, Karnieli E, Rauscher III FJ and LeRoith D: Wild-type and mutant p53 differentially regulate transcription of the insulin-like growth factor I receptor gene. Proc Natl Acad Sci USA 93: 8318-8323, 1996.
112. Frisco M, Hongo A, Rizzo MG, Sacchi A and Baserga R: The insulin-like growth factor I receptor as a physiologically relevant target of p53 in apoptosis caused by interleukin-3 withdrawal. Mol Cell Biol 77: 1084-1092, 1997.
113. Surmacz E, Guvakova M, Nolan M, Nicosia R and Siacca L: Type I insulin-like growth factor receptor function in breast cancer. Breast Cancer Res Treat 47: 255-267, 1998.
114. Umayahara Y, Kawamori R, Watada H, Imano E, Iwama N, Morishima T, Yamasaki Y, Kajimoto Y and Kamada T: Estrogen regulation of the insulin-like growth factor I gene transcription involves an AP-1 enhancer. J Biol Chem 269: 16433-16442, 1994.
115. Osborne CK, Coronado EB, Kittlen LJ, Arteaga CI, Fuqua SA, Ramasharma K, Marshall M and Li CH: Insulin-like growth factor-II (IGF-II): a potential autocrine/paracrine growth factor for human breast cancer acting via the IGF-I receptor. Mol Endocrinol 3: 1701-1709, 1989.
116. Lee AV, Darbre P and King RJ: Processing of insulin-like growth factor-II (IGF-II) by human breast cancer cells. Mol Cel Endocrinol 99: 211-220, 1994.
117. Stewart AJ, Westley BR and May FE: Modulation of the proliferative response of breast cancer cells to growth factors by oestrogen. Br J Cancer 66: 640-648, 1992.
118. McGuire WL Jr, Jackson FG, Figueroa JA, Schimasaki S, Powell DR and Yee D: Regulation of insulin-like growth factor-binding protein (IGFBP) expression by breast cancer cells: use of IGFBP-1 as an inhibitor of insulin-like growth factor action. J Natl Cancer Inst 84: 1336-1341, 1992.
119. Lee AV, Jackson JG, Gooch JL, Hilsenbeck SG, Coronado-Heinsohn E, Osborne CK and Yee D: Enhancement of insulin-like growth factor signaling in human breast cancer: estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo. Mol Endocr 13: 787-796, 1999.
120. Salerno M, Sisci D, Mauro L, Guvakova MA, Ando S and Surmacz E: Insulin receptor substrate 1 is a target for the pure antiestrogen ICI 182,780 in breast cancer cells. Int J Cancer 81: 299-304, 1999.
121. Molloy CA, May FE and Westley BR: Insulin receptor substrate-1 expression is regulated by estrogen in the MCF-7 human breast cancer cell line. J Biol Chem 275: 12565-12571, 2000.
122. Morelli C, Garofalo C, Bartucci M and Surmacz E: Estrogen receptor-alpha regulates the degradation of insulin receptor substrates 1 and 2 in breast cancer cells. Oncogene 22: 4007-4016, 2003.
123. Dupont J, Karas M and LeRoith D: Insulin-like growth factor 1 and oestradiol promote cell proliferation of MCF-7 breast cancer cells: new insights into their synergistic effects. Mol Pathol 54: 149-54, 2001.
124. Jordan VC: Molecular mechanisms of antiestrogen action in breast cancer. Breast Cancer Res Treat 31: 41-52, 1994.
125. Jordan VC: Antiestrogenic action of raloxifene and tamoxifen: today and tomorrow. J Natl Cancer Inst 90: 967-971, 1998.
126. Gronbaek H, Tanos V, Meirow D, Peretz T, Raz I and Flyvbjerg A: Effects of tamoxifen on insulin-like growth factors, IGF binding proteins and IGFBP-3 proteolysis in breast cancer patients. Anticancer Res 23: 2815-2820, 2003.
127. Osborne CK: Tamoxifen in the treatment of breast cancer. New Engl J Med 339: 1609-1618, 1998.
128. Pollak MN, Costantino J, Polychronakos C, Blauer S, Guyda H, Redmond C, Fisher B and Margolese R: Effect of tamoxifen on serum insulinlike growth factor I levels in stage I breast cancer patients. J Natl Cancer Inst 82: 1693-1697, 1990.
129. Pollak MN, Huynh HT and Lefebvre SP: Tamoxifen reduces serum insulin-like growth factor I (IGF-I). Breast Cancer Res Treat 22: 91-100, 1992.
130. Friedl A, Jordan V and Pollak M: Suppression of serum insulin-like growth factor-1 levels in breast cancer patients during adjuvant tamoxifen therapy. Eur J Cancer 29A: 1368-1372, 1993.
131. Huynh HT, Nickerson T, Pollak MN and Yang XF: Regulation of insulin-like growth factor I receptor expression by the pure antiestrogen ICI 182780. Clin Cancer Res 2: 2037-2042, 1996.
132. Tannenbaum GS, Gurd W, Lapointe M and Pollak MN: Tamoxifen attenuates pulsatile growth hormone secretion: mediation in part by somatostatin. Endocrinol 750: 3395-3401, 1992.
133. Huynh HT, Tetenes E, Wallace L and Pollak MN: In vivo inhibition of insulin-like growth factor I gene expression by tamoxifen. Cancer Res 53: 1727-1730, 1993.
134. Daughaday WH and Rotwein P: Insulin-like growth factors I and II. Peptide, messenger ribonucleic acid and gene structures, serum, and tissue concentrations. Endocr Rev 10: 68-91, 1989.
135. Dimitriadis G, Parry Billings M, Bevan S, Dunger D, Piva T, Krause U, Wegener G and Newsholme EA: Effects of insulin-like growth factor I on the rates of glucose transport and utilization in rat skeletal muscle in vitro. Biochem J 285: 269-274, 1992.
136. Isley WL, Underwood LE and Clemmons DR: Dietary components that regulate serum somatomedin-C concentrations in humans. J Clin Invest 71: 175-182, 1983.
137. LeRoith D, Clemmons D, Nissley P and Rechler MM: NIH conference. Insulin-like growth factors in health and disease. Ann Intern Med 116: 854-862, 1992.
138. Bach LA and Rechler MM: Insulin-like growth factors and diabetes. Diabetes Metabol Rev 8: 229-257, 1992.
139. Scheiwiller E, Guler HP, Merryweather J, Scandella C and Maerki W: Growth restoration of insulin-deficient diabetic rats by recombinant human insulin-like growth factor I. Nature 323: 169-171, 1986.
140. Jacob RJ, Sherwin RS, Bowen L, Fryburg D, Fagin KD, Tamborlane WV and Shulman GI: Metabolic effects of IGF-I and insulin in spontaneously diabetic BB/w rats. Am J Physiol 260: E262-E268, 1991.
141. Rossetti L, Frontoni S, Dimarchi R, DeFronzo RA and Giaccari A: Metabolic effects of IGF-I in diabetic rats. Diabetes 40: 444-448, 1991.
142. Sinha MK, Buchanan C, Leggett N, Martín L, Khazanie PG, Dimarchi R, Pories WJ and Caro JF: Mechanism of IGF-I-stimulated glucose transport in human adipocytes. Demonstration of specific IGF-I receptors not involved in stimulation of glucose transport. Diabetes 38: 1217-1225, 1989.
143. Bach MA, Chin E and Bondy CA: The effects of subcutaneous insulin-like growth factor-I infusion in insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 79: 1040-1045, 1994.
144. Peuler JD, Phare SM, Ianucci AR and Hodorek MJ: Differential inhibitory effects of antidiabetic drugs on arterial smooth muscle cell proliferation. Am J Hypertens 9: 188-192, 1996.
145. Tontonoz P, Hu E, Graves RA, Budavari A and Spiegelman BM: mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer. Genes Dev 8: 1224-1234, 1994a.
146. Tontonoz P, Hu E and Spiegelman BM: Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell 79: 1147-1156, 1994b.
147. Sarraf P, Mueller E, Jones D, King FJ, DeAngelo DJ, Partridge JB, Holden SA, Chen LB, Singer S, Fletcher C and Spiegelman BM: Differentiation and reversal of malignant changes in colon cancer through PPAR gamma. Natl Med 4: 1046-1052, 1998.
148. Mueller E, Sarraf P, Tontonoz P, Evans RM, Martin KJ, Zhang M, Fletcher C, Singer S and Spiegelman BM: Terminal differentiation of human breast cancer through PPAR gamma. Mol Cell 1: 465-470, 1998.
149. Pignatelli M, Cortés-Canteli M, Lai C, Santos A and Pérez-Castillo A: The peroxisome proliferator-activated receptor gamma is an inhibitor of ErbBs activity in human breast cancer cells. J Cell Science 114: 4117-4126, 2001.
150. Moschos JJ and Mantzoros CS: The role of the IGF system in cancer: from basic to clinical studies and clinical applications. Oncology 63: 317-332, 2002.
151. Fisher B, Constantino JP, Wickerham DL, Redmond CK, Kavanh M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wicand S, Tan-Chiu E, Ford L and Wolmark N: Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90: 1371-1388, 1998.
152. Miller WH Jr: The emerging role of retinoids and retinoic acid metabolism blocking agents in the treatment of cancer. Cancer 83: 1471-1482, 1998.
153. van Golen CM, Castle VP and Feldman EL: IGF-I receptor activation and Bcl-2 overexpression prevent early apoptotic events in human neuroblastoma. Cell Death Differ 7: 654-665, 2000.